Transdermal and vaginal estradiol for the treatment of menopausal symptoms: the nuts and bolts
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Department of Obstetrics & Gynecology University of Florida College of Medicine–Jacksonville Jacksonville, Florida
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This could be due to the first-pass through the liver with oral MHT, enabling increased triglycerides, coagulation factors, and C-reactive protein, which is minimized with transdermal therapy (211, 212).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [212]
Citations
Cites
Rebar, R. W. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181a66843 · Cited by 234
Transdermal estradiol gel for the treatment of symptomatic postmenopausal women
Archer, D. F., Pickar, J. H., MacAllister, D. C., & Warren, M. P. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31823b8867 · Cited by 28
Estrogen Spray Poses Risks to Children, Pets Through Contact With Treated Skin
Voelker, R. (2010) · JAMA · doi:10.1001/jama.2010.1227 · Cited by 15
Further evidence for promoting transdermal estrogens in the management of postmenopausal symptoms
Canonico, M., & Scarabin, P. (2011) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31822d6677 · Cited by 4
Cited by
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho, L., Kaunitz, A. M., Faubion, S. S., Hayes, S. N., Lau, E. S., Pristera, N., Scott, N., Shifren, J. L., Shufelt, C. L., Stuenkel, C. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061559 · Cited by 205
Self-citationManagement of Menopausal Symptoms
Kaunitz, A. M., & Manson, J. E. (2015) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000001058 · Cited by 191
“Our clinical experience suggests that in young highly symptomatic postmenopausal women, E2 levels below this range may not result in adequate symptom relief.(32) Medical and iatrogenic conditions that can cause heat intolerance or the sensation of flushing”
BackgroundSelf-citationTreatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause
Kaunitz, A. M., Kapoor, E., & Faubion, S. S. (2021) · JAMA · doi:10.1001/jama.2021.3305 · Cited by 41
Self-citationTransdermal delivery of bioidentical estrogen in menopausal hormone therapy: a clinical review
Files, J. A., & Kling, J. M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1700949 · Cited by 26
Lee, A. A., & Den Hartigh, L. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1682231 · Cited by 32
“Developing therapies require the precision of understanding the interplay between the human hormonal milieu and metabolic health to manage metabolic dysfunction in diverse populations.”
Low-dose transdermal estradiol for vasomotor symptoms: a systematic review
Corbelli, J. A., Shaikh, N., Wessel, C. B., & Hess, R. (2014) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000258 · Cited by 24
Contraception for midlife women
Allen, R. H., & Cwiak, C. A. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000584 · Cited by 14
Assessment of estrogen exposure from transdermal estradiol gel therapy with a dried urine assay
Newman, M. S., Curran, D. A., Mayfield, B. P., Saltiel, D., & Stanczyk, F. Z. (2022) · Steroids · doi:10.1016/j.steroids.2022.109038 · Cited by 8
Newman, M. S., Mayfield, B. P., Saltiel, D., & Stanczyk, F. Z. (2022) · Steroids · doi:10.1016/j.steroids.2022.109149 · Cited by 7
“Of the available options for transdermal estrogen delivery systems, the transdermal estradiol (E2) patch is one of the most commonly used [5,6].”
BackgroundMenopause Hormone Therapy: 30 Years of Advances and Controversies
Schwartz, A. M., Sweeney, M. E., Dolan, M., & Lundberg, G. P. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.10.011 · Cited by 3
Compounded bioidentical hormone therapy
Kaunitz, A. M., & Kaunitz, J. D. (2015) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000484 · Cited by 1
Self-citationMenopausal Hormone Therapy—Transdermal or Oral
Hadžić, D., & Bolanča, I. (2025) · Science, Art and Religion. · doi:10.5005/jp-journals-11005-0125
Transdermal Hormonal Therapy in Menopause: Current Evidence and Personalized Approaches
Mihai, M. M., Toma, A.-M., Toma, C.-V., Copilău, A. I., Naum, C.-I., Timofte, M.-A., Văcăroiu, I. A., Stroescu, A.-E. B., Sima, R. M., & Poenaru, M. O. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050529 · Cited by 1
“In the United States, oral estrogen therapy continues to represent the predominant form of hormone replacement treatment [21,33].”
Kim, K., & Park, H. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1847250
“This is important, as prior studies have demonstrated that risks and benefits vary by formulation (22–24), and international trends indicate shifts toward vaginal, transdermal, and lower-dose therapies (12, 23, 24).”
Metadata
- Authors
- Kaunitz, A. M.
- Affiliations
- University of Florida (US)
- Corresponding author
- Kaunitz, Andrew M.
- ORCID
- Kaunitz, Andrew M.
- Venue
- Menopause
- Published
- 2012-06
- Volume
- 19
- Issue
- 6
- Pages
- 602-603
- ISSN
- 1072-3714 (ISSN-L)
- OpenAlex
- W2318633984
- Cited by
- 14
- References
- 4
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 1 · 2022: 2 · 2021: 1 · 2019: 1 · 2015: 3 · 2014: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Menopause The Journal of The North American Menopause Society (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Keywords
- transdermal estradiol, vaginal estradiol, menopausal symptoms, menopause, hormone replacement therapy
- MeSH terms
- Administration, Cutaneous, Estrogens, Female, Humans, Progestins, Thrombin, Estrogen Replacement Therapy, Postmenopause, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.